Anima Nanda

Alzheimer’s disease (AD) is a devastating neurodegenerative disorder defined by progressive memory loss and synaptic failure. For decades, therapeutic development has focused on clearing amyloid-beta plaques, yet the repeated clinical failures of this approach necessitate a fundamental paradigm shift toward the brain’s immunometabolic landscape. The “Viral Mimicry” hypothesis posits that AD represents a state of sterile autoimmunity where the innate immune system mistakenly identifies self-nucleic acids as viral pathogens. This “ghost war” is ignited by the convergence of metabolic dysfunction and genomic instability: specifically, the leakage of mitochondrial DNA into the cytosol and the epigenetic derepression of ancient retrotransposons (LINE-1, HERVs). These endogenous ligands activate the cGAS-STING cytosolic sensing axis, a pathway that drives a chronic interferon response. Consequently, microglia and astrocytes are transformed into senescent, pro-inflammatory phenotypes that release a toxic Senescence-Associated Secretory Phenotype (SASP), directly fueling synaptic elimination. Crucially, major genetic risk factors, including APOE4 and TREM2 variants, exacerbate this cascade by compromising mitochondrial integrity and lipid metabolism, thereby sensitizing the brain to innate surveillance failure. By reconceptualizing AD as an acquired interferopathy driven by the “enemy within,” this framework highlights novel therapeutic targets. Specifically, repurposing Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to block retrotransposition and deploying senolytics to clear dysfunctional glia offer promising strategies to arrest the progression from healthy aging to cognitive decline. This review synthesizes current research on the molecular mechanisms of viral mimicry, detailing the impact of genetic risk factors and evaluating emerging therapeutic interventions targeting this innate immune axis. Graphical Abstract The alternative text for this image may have been generated using AI. The Shift from Molecular Containment to Viral Mimicry in Alzheimer’s Disease. The figure contrasts the physiological state of healthy aging with the pathological state of Alzheimer’s Disease. (Left) In the healthy brain, "Molecular Containment" is maintained: immunogenic mitochondrial DNA is sequestered within the organelle, and ancient retrotransposons are epigenetically silenced within the nucleus. (Right) In Alzheimer’s Disease, the convergence of genomic instability and metabolic failure leads to a "loss of inhibition". The derepression of retroelements (LINE-1 (long interspersed nuclear element-1) dsDNA, HERV dsRNA) and the leakage of mitochondrial DNA into the cytosol activate the cGAS-STING innate immune axis. This viral mimicry transforms microglia into a senescent, Lipid-Droplet Accumulating phenotype, driving a chronic Type I Interferon response that fuels neurodegeneration

Alzheimer’s disease is a multifaceted neurodegenerative condition marked by the build-up of amyloid plaques and neurofibrillary tangles that lead to progressive cognitive impairment. Neuroinflammation, especially the activation of microglia, plays a pivotal part in driving this pathology. Microglia are the brain’s resident immune cells and can adopt a spectrum of activation states that support either neuroprotection or neurodegeneration. Evidence shows that their phenotypes are highly dynamic and shaped by environmental influences and pathological signals. During the early phases of the disease, microglia tend to assume anti-inflammatory roles that facilitate plaque clearance and promote tissue recovery. Prolonged or dysregulated activation, however, shifts them toward a pro-inflammatory state that amplifies neuronal damage. Several molecular pathways including JAK STAT, PI3K AKT, and MAPK are central to regulating these processes and have emerged as promising therapeutic targets. This review summarizes current insights into microglial phenotypic transitions, the signaling mechanisms governing their activation, and the therapeutic potential of modulating neuroinflammation. Enhancing the neuroprotective capacity of microglia, suppressing chronic inflammatory responses, and targeting key receptors such as TREM2 and P2 × 7 represent potential strategies. A deeper understanding of microglial interactions with other glial cells and the molecular drivers of their activation may provide new avenues for slowing or halting the progression of Alzheimer’s disease and related neurodegenerative disorders. Graphical Abstract Resting microglia become activated and polarize toward either anti-inflammatory (neuroprotective) or pro-inflammatory (neurotoxic) phenotypes. Early stages of AD are characterized by protective microglial responses, while MCI and late stages show predominant pro-inflammatory activity. Key signaling pathways involved include JAK/STAT, PI3K/AKT, MAPK, TREM2, TLRs, and purinergic receptors (P2 × 7, P2Y12). Therapeutic strategies aim to inhibit chronic inflammation (e.g., TLR4 and PI3K/AKT inhibitors) or enhance microglial neuroprotective functions (e.g., TREM2 activation and purinergic receptor modulation).

Ovarian cancer remains one of the most lethal malignancies affecting women, largely due to its asymptomatic onset and frequent diagnosis at advanced stages. Emerging evidence has underscored the pivotal role of kinesin superfamily proteins (KIFs) in orchestrating the cellular mechanisms underlying tumor initiation and progression, particularly in ovarian cancer. These microtubule-associated motor proteins are essential for intracellular transport, cell division, signal transduction, and organelle positioning. Dysregulation of KIFs has been implicated in enhanced cellular proliferation, metastasis, and resistance to chemotherapy. In ovarian cancer, specific KIF members have been shown to promote cell motility and interfere with key signaling pathways, thereby accelerating tumor progression. Elevated expression levels of certain KIFs correlate with poor patient prognosis and reduced overall survival. This review consolidates current insights into the role of KIFs in ovarian cancer pathogenesis and emphasizes their potential as therapeutic targets. Elucidating the mechanistic involvement of KIFs in this malignancy may pave the way for innovative diagnostic, prognostic, and therapeutic strategies aimed at improving clinical outcomes in this highly aggressive cancer type. Graphical Abstract